“health is the first duty of life”
ImmunePharma S.r.l. is an academic spin-off of Department of Pharmacy, University of Salerno, Italy, corporated in 2015. The ImmunePharma S.r.l. is an academic spin-off that operates in the design, development and production of medical device for diagnostic/prognostic and new drugs against the lung cancer.
The idea arose by the valorization of the research results achieved over the years by the shareholders.
The business idea initiates with the discovery of a new inflammatory pathway involved in formation and growth of tumor in the lung (patent N. RM2014A000080 and N. PCT/IB2015/051262) by academic researchers who have given birth to the Company.
In this light, the Company operates in the field of oncology with the specialization of diagnosis/prognosis and therapy of lung cancer.
The core activity is the development of innovative non-invasive diagnostic and prognostic methods carried out on a simple blood test and/or other biological fluid.
Moreover, the ImmunePharma s.r.l. has expertise in medicinal chemistry and drug delivery to develop and produce new selective small molecule drugs, able to inhibit the target protein identified as a specific biomarker for lung carcinogenesis, in appropriate pharmaceutical formulations.